Zofran (ondansetron) causes constipation because it blocks serotonin receptors that your gut relies on to push food forward. About 95% of your body’s serotonin is produced in the digestive tract, where it plays a central role in triggering the wave-like muscle contractions that move stool through your intestines. When Zofran blocks those signals to control nausea, it simultaneously slows everything down. In clinical studies, ondansetron increased whole gut transit time by an average of 10 hours compared to placebo.
How Serotonin Drives Your Gut
Your intestinal lining contains specialized cells that release serotonin in response to pressure from food passing through. That serotonin activates receptors on nearby nerve cells, particularly a type called 5-HT3 receptors, which trigger the peristaltic reflex: a coordinated squeeze-and-relax pattern that propels contents forward. Serotonin also stimulates fluid secretion into the intestine, which keeps stool soft and easier to move.
This system is essentially a communication network. Serotonin is the signal that tells the muscles in your gut wall when and how forcefully to contract. Without it, the whole process slows down considerably.
What Zofran Does to That System
Zofran is a 5-HT3 receptor antagonist, meaning it sits on those same serotonin receptors and prevents serotonin from activating them. That’s what makes it so effective at stopping nausea: it blocks the serotonin signals that travel from the gut to the brain’s vomiting center. But because those same receptors also control propulsive motility in the intestines, blocking them reduces the frequency and strength of peristaltic contractions.
The result is that stool spends more time sitting in the colon, where your body continues absorbing water from it. The longer it sits, the harder and drier it becomes. A randomized trial published in Gut found that patients on ondansetron had gut transit times roughly 10 hours longer than those on placebo, with the difference being highly statistically significant. That’s a meaningful delay, and it directly translates to firmer, less frequent stools.
How Common Constipation Is on Zofran
The constipation rate depends heavily on how the drug is dosed. When patients take a fixed dose without the ability to adjust it, about 1 in 4 develop significant constipation. But when patients can titrate their dose up or down based on symptoms, constipation drops to around 9%, and only about 2% find it severe enough to stop taking the medication altogether. This comes from a large randomized trial funded by the UK’s National Institute for Health and Care Research.
For context, fewer than 10% of patients taking ondansetron for nausea in clinical trials reported constipation, likely because those courses tend to be shorter (a few days around chemotherapy or surgery) rather than ongoing daily use.
This Is a Class Effect, Not Unique to Zofran
All drugs that block 5-HT3 receptors carry a constipation risk. A systematic review and meta-analysis in PLOS ONE found that as a class, 5-HT3 antagonists made patients nearly four times more likely to develop constipation compared to placebo. The rates varied by specific drug: alosetron (used for irritable bowel syndrome) caused constipation in 23% of patients versus 5% on placebo, while ramosetron caused it in 9% versus 3%. Ondansetron tends to fall on the lower end of that range because it’s typically used in shorter courses and at lower doses than drugs designed for chronic gut conditions.
The flip side of this mechanism is actually therapeutic. Some doctors now prescribe low-dose ondansetron specifically for patients with diarrhea-predominant irritable bowel syndrome, taking advantage of the slowing effect to reduce urgency and stool frequency.
Who Is More Likely to Be Affected
If you already tend toward infrequent bowel movements or have a history of constipation, Zofran will amplify that tendency. The FDA label specifically warns that using ondansetron after abdominal surgery or during chemotherapy can mask a developing bowel obstruction, since the drug suppresses the very motility signals your body would normally use to push through a blockage. People with risk factors for gastrointestinal obstruction need closer monitoring.
Higher doses carry more risk. The FDA label documents a case where a single large intravenous dose of 72 mg caused severe constipation alongside other serious side effects. While that dose is far above what’s normally prescribed, it illustrates the dose-dependent nature of the problem.
Pregnancy is another common context. Many people take Zofran for severe morning sickness, and pregnancy itself already slows gut motility due to hormonal changes. Adding a serotonin blocker on top of that can make constipation particularly stubborn.
Managing Constipation While Taking Zofran
The most effective strategy is prevention rather than treatment after the fact. A daily stool softener like docusate or magnesium citrate (or both) is commonly recommended for anyone taking ondansetron regularly. The goal is to counteract the water absorption that happens when stool moves too slowly, keeping it soft enough to pass without straining.
Staying well hydrated matters more than usual here, since your colon is pulling extra water from stool that’s spending more time in transit. Fiber intake helps, but it works best when paired with adequate fluids. Without enough water, adding fiber can actually worsen the problem.
If you’re on an adjustable dose, reducing it slightly often resolves constipation without losing the anti-nausea benefit. Clinical trial data supports this: when patients were allowed to titrate their own dose, severe constipation was rare, and most people who experienced it improved with a dose reduction rather than needing to stop the drug entirely. For people dealing with more severe cases, particularly during pregnancy with hyperemesis, a bowel stimulant such as an enema up to three times a week is sometimes necessary alongside IV fluids.
The constipation typically resolves once you stop taking Zofran, since the serotonin receptors in your gut return to normal function relatively quickly. For short courses around surgery or chemotherapy, most people find the issue is temporary and manageable.